EP0958835A1 — Preventive/remedy for frequent urination and urinary incontinence
Assigned to Kissei Pharmaceutical Co Ltd · Expires 1999-11-24 · 26y expired
What this patent protects
The present invention relates to a novel drug for the prevention or treatment of pollakiuria and urinary incontinence which comprises as an active ingredient a β 3 -adrenoceptor stimulating agent, which exerts potent relaxing effects on human bladder smooth muscle.
USPTO Abstract
The present invention relates to a novel drug for the prevention or treatment of pollakiuria and urinary incontinence which comprises as an active ingredient a β 3 -adrenoceptor stimulating agent, which exerts potent relaxing effects on human bladder smooth muscle.
Drugs covered by this patent
- Myrbetriq (MIRABEGRON) · Apgdi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.